You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
4F 4PP oxalate
Biological Activity for 4F 4PP oxalate
4F 4PP oxalate is a selective 5-HT2A antagonist with almost as high affinity (Ki = 5.3 nM) as ketanserin but with a much lower affinity for 5-HT2C sites (Ki = 620 nM).
Compound Libraries for 4F 4PP oxalate
Technical Data for 4F 4PP oxalate
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for 4F 4PP oxalate
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for 4F 4PP oxalate
The following data is based on the product molecular weight 429.49. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.33 mL||11.64 mL||23.28 mL|
|5 mM||0.47 mL||2.33 mL||4.66 mL|
|10 mM||0.23 mL||1.16 mL||2.33 mL|
|50 mM||0.05 mL||0.23 mL||0.47 mL|
References for 4F 4PP oxalate
References are publications that support the biological activity of the product.
Hagberg et al (1998) Stimulation of 5-HT2A receptors on astrocytes in primary culture opens voltage-independent Ca2+ channels. Neurochem.Int. 32 153 PMID: 9542727
Herndon et al (1992) Ketanserin analogues - structure affinity relationships of 5HT2 and 5HT1C serotonin receptor binding. J.Med.Chem. 35 4903 PMID: 1479590
If you know of a relevant reference for 4F 4PP oxalate, please let us know.
View Related Products by Product Action
Keywords: 4F 4PP oxalate, 4F 4PP oxalate supplier, Selective, 5-HT2A, antagonists, Serotonin, Receptors, 5-HT2, 4F4PP, oxalate, 0523, Tocris Bioscience
3 Citations for 4F 4PP oxalate
Citations are publications that use Tocris products. Selected citations for 4F 4PP oxalate include:
Rodríguez-Muñoz et al (2018) Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget 9 23373 PMID: 29805740
Lee et al (2018) Peripheral serotonin receptor 2B and transient receptor potential channel 4 mediate pruritus to serotonergic antidepressants in mice. J Allergy Clin Immunol 142 1349 PMID: 29920354
Gerhold et al (2015) Pronociceptive and Antinociceptive Effects of Bupren. in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude. J Neurosci 35 9580 PMID: 26134641
Do you know of a great paper that uses 4F 4PP oxalate from Tocris? Please let us know.
Reviews for 4F 4PP oxalate
There are currently no reviews for this product. Be the first to review 4F 4PP oxalate and earn rewards!
Have you used 4F 4PP oxalate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.